¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â Á¦73Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-04-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â Á¦73Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-04-20
±³À°ÀÏÀÚ : 2022-04-20
±³À°Àå¼Ò : ±×·£µå ÇöóÀÚ Ã»ÁÖ È£ÅÚ  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2022³â Á¦73Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡   (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)  
Áö¿ª : Ãæû³²µµ
±³À°½Ã°£ : 20 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í ¿ÀÇÁ¶óÀÎ Á¤È¸¿ø 70,000 ÁØȸ¿ø 30,000 / ¿Â¶óÀÎ Á¤È¸¿ø 50,000 ÁØȸ¿ø20,000 ¸¸65¼¼ ÀÌ»ó ¸éÁ¦ / ºñȸ¿ø 500,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 13:10~13:30 From university to venture  ÀÌÁõÈÆ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 14:00~14:05 Introduction  Chair() 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 14:05~14:50 ÀÚº»ÁÖÀÇ¿Í ÅõÀÚ  ¹Ú¼¼ÀÍ(ü½½¸®ÀÚ¹®) 
Åä·Ð 04-20 ±×·£µåº¼·ëAB 14:50~15:00 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 10:30~10:47 New horizon of wound healing  ½ÅÁ¤¿ì(Â÷ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 10:47~11:04 Acute wound management: minimization of scarring  ½ÅÁ¤¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 11:04~11:21 Chronic wound: how to treat  ±èÈƼö(ºÎ»êÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëC 11:21~11:30 Q&A  () 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 14:00~14:50 Let¡¯s study health care big data analyses  ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú) 
Åä·Ð 04-20 Á÷ÁöȦ 14:50~15:00 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:00~14:05 Overview  Chair() 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:05~14:20 Mast cell and urticaria: how mast cell induces urticaria  ÃÖÁ¾¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:20~14:35 Targeting extracellular mediators for urticaria treatment (biologics)  È«Á¾¼ö(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:35~14:50 Targeting receptors and intracellular signaling (small molecule inhibitors)  ¼­Çö¹Î(ÇѾçÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëC 14:50~15:00 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 15:30~15:35 Overview  ¼Õ»ó¿í(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 15:35~15:50 New insights into AD in children  °íÇöâ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 15:50~16:05 What¡¯s the difference between children¡¯s AD and adults¡¯ AD?  ÀüÁöÇö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:05~16:20 Recent advances on the treatment of AD in children  ³ªÂùÈ£(Á¶¼±ÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëC 16:20~16:30 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:30~16:35 Overview  Chair() 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:35~16:50 Best practices in treating psoriasis in sensitive areas  º¯Áö¿¬(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:50~17:05 Assessing and managing comorbidities associated with psoriasis  ±èÁ¤Àº(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 17:05~17:20 Treatment in patients with biologic failure  ÃÖÀ¯¼º(¿ï»êÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëC 17:20~17:30 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 09:30~09:42 Á¶Á÷ °Ë»ç, ¸é¿ªÇü±¤°Ë»ç  ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 09:42~09:54 Áø±Õ  È«Á¾¼ö(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 09:54~10:06 ±¤°Ë»ç  ¹éÀ¯»ó(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:06~10:18 Ã¸Æ÷°Ë»ç  ±èÁ¤Àº(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:18~10:30 ´õ¸ð½ºÄÚÇǰ˻砠½Å±âÇõ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:30~10:42 ½ºÅ×·ÎÀ̵堠À̽ÃÇü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:42~10:54 Ç×Áø±ÕÁ¦/Ç×»ýÁ¦  ¼­Çö¹Î(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:54~11:06 ¸é¿ª¾ïÁ¦Á¦  Á¤º¸¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:06~11:18 ·¹Æ¼³ëÀ̵堠±èűÕ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:18~11:30 Ç×È÷½ºÅ¸¹ÎÁ¦  ±Ç¼øÈ¿(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 09:30~09:35 Introduction  Chair() 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 09:35~10:20 ½É»çÀÚ¿Í ÆíÁýÀÎÀ» À§ÇÑ ¿¬±¸ÃâÆÇÀ±¸®  À¯ ¿µ(°í·ÁÀÇ´ë ¼Ò¾Æû¼Ò³â°ú/ÀÇÆíÇù ÃâÆÇÀ±¸®À§¿øÀå) 
Åä·Ð 04-20 ±×·£µåº¼·ëC 10:20~10:30 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 15:30~16:20 ¼Ò¾Æ¿¡¼­ ÈçÇÑ ÇǺÎÁúȯÀÇ Áø´Ü°ú Ä¡·á  ±è±ÔÇÑ(¼­¿ïÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëAB 16:20~16:30 Q&A  () 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 15:30~15:55 Postnatal epigenetic regulation of dermal fibroblast maturation  ±Ç¿À»ó(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 15:55~16:20 The role of profilin-1 in the pathogenesis of psoriasis  ±èµ¿Çö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 16:20~16:45 CRTC3, a sensor and key regulator for melanogenesis  À强Àº(¿ï»êÀÇ´ë) 
Åä·Ð 04-20 ¿ì¾ÏȦ 16:45~17:00 Q&A  () 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 09:30~09:35 Overview  Chair() 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 09:35~09:50 Laser safe use guidance - laser hazard classification  ³ªÁ¤ÀÓ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 09:50~10:05 Avoid unwanted laser complications - case review  ±èÇý¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 10:05~10:20 Protect yourself from virus: recommendations for cutaneous laser during COVID-19 pandemic  ±Ç¼øÈ¿(°æÈñÀÇ´ë) 
Åä·Ð 04-20 ¿ì¾ÏȦ 10:20~10:30 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 13:30~13:35 Introduction  Chair() 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 13:35~13:55 Quantitative and qualitative assessment of chronic pruritus  Àå¿ëÇö(°æºÏÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëAB 13:55~14:00 Q&A  () 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 13:30~13:35 Introduction  Chair() 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 13:35~13:55 The spatially resolved transcriptome profile of cutaneous CD30 positive lymphoproliferative disorder  ÀÌ¿ìÁø(¿ï»êÀÇ´ë) 
Åä·Ð 04-20 Á÷ÁöȦ 13:55~14:00 Q&A  () 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:00~17:04 Introduction  Chair() 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:04~17:21 Inflammatory disease on head and neck  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:21~17:38 Benign tumors on head and neck  ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:38~17:55 Malignant tumors on head and neck  À±¼÷Á¤(Àü³²ÀÇ´ë) 
Åä·Ð 04-20 Á÷ÁöȦ 17:55~18:00 Q&A  () 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 15:30~15:55 Atrophic acne scar treatment: practical tips  À̵µ¿µ(¸®´õ½ºÇǺΰú °Ç´ëÁ¡) 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 15:55~16:20 Skills not to be missed: filler (filler, just remember this)  ³ëÈ¿Áø(³ªÀǹ̷¡ÇǺΰú) 
±³À°½Ã°£ 04-20 Á÷ÁöȦ 16:20~16:45 Skincare tips in acne patients  ³ë¼º¹Î(¿¬¼¼ÆĽºÅÚÇǺΰú) 
Åä·Ð 04-20 Á÷ÁöȦ 16:45~17:00 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 16:30~17:20 ÀÇ·áºÐÀï»ç·Ê  ·ù¿µ¿í(°è¸íÀÇ´ë) 
Åä·Ð 04-20 ±×·£µåº¼·ëAB 17:20~17:30 Q&A  () 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:30~11:33 Introduction  Chair() 
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:33~12:00 Real world clinical experiences of dupilumab in pediatric AD patients  Elaine Siegfried(Saint Louis University USA) 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 10:30~10:33 Introduction  Chair() 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 10:33~11:18 Onychomycosis treatment update  Á¤ÇýÁ¤(±¹¸³Áß¾ÓÀÇ·á¿ø) 
Åä·Ð 04-20 ¿ì¾ÏȦ 11:18~11:30 Q&A  () 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 14:00~14:50 Why do we need to consider early intervention in psoriatic disease?  ±èűÕ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 04-20 ¿ì¾ÏȦ 14:50~15:00 Q&A  () 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 17:00~17:25 Evolving treatments for moderate to severe atopic dermatitis  °íÇöâ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 17:25~17:50 Real life experience of baricitinib in patients with moderate to severe atopic dermatitis  ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø) 
Åä·Ð 04-20 ¿ì¾ÏȦ 17:50~18:00 Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â Á¦73Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-04-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÅëÁõÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2022-04-21
´ÙÀ½±Û ¿øÀڷº´¿ø (¿Â¶óÀÎ) 2022³âµµ 1Â÷ ¹æ»ç¼±ºñ»óÁø·á ½Å±Ô±³À°(ºñ´ë¸é) 2ÀÏÂ÷ : 2022-04-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21182 °æ±â Á¦6ȸ °¡Å縯´ëÇб³ ¼ººó¼¾Æ®º´¿ø ¾Ï ½ÉÆ÷Áö¾ö(¿ÀÇÁ¶óÀÎ/¿Â¶óÀÎ) : 2024-07-26 0 6 2024-07-02
21181 ´ë±¸ Çѱ¹¿©ÀÚÀÇ»çȸ ´ë±¸°æºÏÁöȸ 7¿ù Çмú½ÉÆ÷Áö¾ö(ºÒ¸éÁõ, ¼ö¸éÁ¦, Ȳ¹Ýº¯¼º ¹× ³ëÈ­ °ü·Ã ¾ÈÁúȯ) : 2024-07-23 0 12 2024-07-02
21180 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ) Á¦12ȸ ¼­¿ï ÀÓ»ó¾îÁö·³Áõ ¼¼¹Ì³ª : 2024-07-21 0 11 2024-07-02
21179 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ÇнÀÀå¾Ö ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-07-21 0 15 2024-07-02
21178 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°ú½ºÆ÷Ã÷ÀÇÇÐȸ - Á¦2Â÷ ½ºÆ÷Ã÷ ¼Õ»ó ½ÉÆ÷Áö¾ö : 2024-07-21 0 8 2024-07-02
21177 ¼­¿ï PH Korea 2024 with 4th EASOPH(Á¦9ȸ Æó°íÇ÷¾Ð Çмú´ëȸ) (2ÀÏÂ÷) : 2024-07-20 0 5 2024-07-02
21176 ¼­¿ï ´ëÇѽŰæ±Ù°ñ°áÃÊÀ½ÆÄÇÐȸ Á¦2ȸ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-07-20 0 7 2024-07-02
21175 ¼­¿ï 21st Head and Neck Workshop (»ï¼º¼­¿ïº´¿ø & ´ëÇѵΰæºÎ¿Ü°úÇÐȸ) : 2024-07-20 0 6 2024-07-02
21174 ¼­¿ï 2024 ´ëÇÑÈ£Èí°ü¸®ÇÐȸ Á¦32Â÷ Çмú´ëȸ : 2024-07-20 0 7 2024-07-02
21173 ¼­¿ï 2024³â ´ëÇÑ°íÇ÷¾ÐÇÐȸ ´ë»çÁõÈıº¿¬±¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-07-20 0 9 2024-07-02
21172 ¼­¿ï Á¦4ȸ ´ëÇѼÒÈ­±âÇÐȸ °æ±âÀÎõÁöȸ ½ÉÆ÷Áö¾ö ¹× ¿¬±¸°úÁ¦ ¹ßǥȸ : 2024-07-20 0 8 2024-07-02
21171 ¼¼Á¾ 2024³â ´ëÇÑ°í°üÀýÇÐȸ °üÀýº¸Á¸ ½ÉÆ÷Áö¿ò : 2024-07-20 0 6 2024-07-02
21170 ¿ï»ê 2024³â Á¦7ȸ ´ëÇÑÇ׳ëÈ­ºñ´¢ÅëÇÕ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-20 0 8 2024-07-02
21169 ¼­¿ï PH Korea 2024 with 4th EASOPH(Á¦9ȸ Æó°íÇ÷¾Ð Çмú´ëȸ) (1ÀÏÂ÷) : 2024-07-19 0 5 2024-07-02
21168 ¼­¿ï ´ëÇÑ»çȸÁ¤½ÅÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-19 0 13 2024-07-01
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷